TMDX (TransMedics Group, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by TMDX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-14 | Nicholas Corcoran | See remarks | A | — | — |
| 2026-07-14 | Gerardo Hernandez | Chief Financial Officer | A | — | — |
| 2026-07-14 | Waleed H Hassanein | President & CEO | A | — | — |
| 2026-06-17 | Thomas J. Gunderson | Director | MIXED | — | — |
| 2026-05-22 | MERILEE RAINES | Director | A | — | — |
| 2026-05-22 | Edward M Basile | Director | A | — | — |
| 2026-05-22 | David Weill | Director | A | — | — |
| 2026-05-22 | JAMES R TOBIN | Director | A | — | — |
| 2026-05-22 | Stephanie Lovell | Director | A | — | — |
| 2026-05-22 | Thomas J. Gunderson | Director | A | — | — |
| 2026-05-22 | Edwin Kania | Director | A | — | — |
| 2026-05-21 | Matthew S. Forsyth | See Remarks | A | — | — |
| 2026-03-06 | Stephanie Lovell | Director | Sell | — | — |
| 2026-03-06 | David Weill | Director | MIXED | — | — |
| 2026-03-04 | Anil P. Ranganath | See remarks | Sell | — | — |
| 2026-03-04 | Nicholas Corcoran | See remarks | MIXED | — | — |
| 2026-03-04 | Gerardo Hernandez | Chief Financial Officer | MIXED | — | — |
| 2026-02-20 | Giovanni Cecere | Chief Commercial Officer | A | — | — |
| 2025-12-05 | Gerardo Hernandez | Chief Financial Officer | Sell | — | — |
| 2025-12-05 | David Weill | Director | MIXED | — | — |
| 2025-11-26 | Anil P. Ranganath | See remarks | MIXED | — | — |
| 2025-11-18 | Waleed H Hassanein | President & CEO | Buy | — | — |
| 2025-10-31 | Edward M Basile | Director | MIXED | — | — |
| 2025-08-08 | Waleed H Hassanein | President & CEO | Buy | — | — |
| 2025-08-05 | Edward M Basile | Director | MIXED | — | — |
| 2025-06-10 | Anil P. Ranganath | See remarks | Sell | — | — |
| 2025-05-29 | Edward M Basile | Director | MIXED | — | — |
| 2025-05-23 | MERILEE RAINES | Director | A | — | — |
| 2025-05-23 | EDWIN M JR KANIA | Director | A | — | — |
| 2025-05-23 | Stephanie Lovell | Director | A | — | — |
| 2025-05-23 | Thomas James Gunderson | Director | A | — | — |
| 2025-05-23 | David Weill | Director | MIXED | — | — |
| 2025-05-23 | Edward M Basile | Director | A | — | — |
| 2025-05-23 | JAMES R TOBIN | Director | A | — | — |
| 2025-05-13 | Edward M Basile | Director | MIXED | — | — |
| 2025-03-05 | Tamer I Khayal | Chief Commercial Officer | Sell | — | — |
| 2025-02-26 | Nicholas Corcoran | See Remarks | A | — | — |
| 2025-02-26 | Anil P. Ranganath | See remarks | A | — | — |
| 2025-02-26 | Tamer I Khayal | Chief Commercial Officer | A | — | — |
| 2025-02-26 | Waleed H Hassanein | President & CEO | A | — | — |
| 2025-02-26 | Gerardo Hernandez | Chief Financial Officer | A | — | — |
| 2025-01-10 | Tamer I Khayal | Chief Commercial Officer | MIXED | — | — |
| 2024-12-11 | Gerardo Hernandez | Chief Financial Officer | A | — | — |
| 2024-12-04 | Tamer I Khayal | Chief Commercial Officer | MIXED | — | — |
| 2024-11-13 | Tamer I Khayal | Chief Commercial Officer | MIXED | — | — |
| 2024-11-07 | Edward M Basile | Director | MIXED | — | — |
| 2024-11-05 | Tamer I Khayal | Chief Commercial Officer | MIXED | — | — |
| 2024-10-17 | Waleed H Hassanein | President & CEO | MIXED | — | — |
| 2024-10-03 | Tamer I Khayal | Chief Commercial Officer | MIXED | — | — |
| 2024-09-17 | JAMES R TOBIN | Director | G | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 3,499,859 | — |
| — | 10%+ Owner | 3,411,376 | — |
| — | 10%+ Owner | 2,053,240 | — |
| — | President & CEO | 516,102 | — |
| — | Director | 309,874 | — |
| — | 10%+ Owner | 214,285 | — |
| — | Director | 162,127 | — |
| — | See remarks | 41,558 | — |
| — | Chief Commercial Officer | 36,042 | — |
| — | Chief Financial Officer | 31,935 | — |
| — | Director | 26,266 | — |
| — | VP, Global Regulatory Affairs | 23,943 | — |
| — | Chief Financial Officer | 23,359 | — |
| — | Chief Commercial Officer | 19,057 | — |
| — | See Remarks | 15,409 | — |
| — | Director | 15,056 | — |
| — | VP of Operations | 14,473 | — |
| — | VP of Quality & Engineering | 14,273 | — |
| — | See remarks | 13,091 | — |
| — | Director | 6,981 | — |
| — | Director | 5,788 | — |
| — | Director | 5,788 | — |
| — | VP, Clinical Affairs | 5,685 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the TMDX quote page; the site-wide leaderboard is on the insider transactions hub.